Fosun International Lands Spot on Fortune's 2026 Most Admired Chinese Companies List
Event summary
- Fosun International included in Fortune China's 2026 Most Admired Chinese Companies list, highlighting ESG leadership and stakeholder value creation.
- Fosun's MSCI ESG rating upgraded to AAA, Hang Seng Sustainability Rating remains at AA-, and FTSE Russell ESG score rises to 4.2.
- Fosun Pharma's luvometinib tablets (FUMAINING) approved for two rare disease indications in China, with Phase III study data to be presented at ASCO 2026.
- Henlius' HLX43 ADC showcases promising PFS data in NSCLC, with international clinical trials advancing across multiple regions.
- Fosun commits to peaking carbon emissions by 2028 and achieving carbon neutrality by 2050, with 97% of Club Med resorts obtaining Green Globe Certification.
The big picture
Fosun International's inclusion in Fortune's 2026 Most Admired Chinese Companies list underscores its strategic focus on ESG leadership and innovation-driven growth. The company's advancements in rare disease treatments and ADC development position it as a key player in the global healthcare sector, while its commitment to carbon neutrality aligns with broader sustainability trends. Fosun's ability to balance innovation with social responsibility will be critical in maintaining its competitive edge in an increasingly ESG-conscious market.
What we're watching
- ESG Leadership
- How Fosun's sustained ESG performance will impact its competitive positioning in the Chinese corporate landscape.
- Healthcare Innovation
- Whether Fosun Pharma can maintain its momentum in rare disease treatments and ADC development.
- Sustainability Transition
- The pace at which Fosun can achieve its carbon neutrality goals and the scalability of its sustainability initiatives.
Related topics